Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Climb Bio, Inc.NASDAQ: CLYM
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $15.17M fell 34.1% year over year, ahead of the -41.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 21.2% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -34.1% holds above the trailing-twelve-month pace of -41.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 67.79M USD
- Year-over-year change
- -17.4%
- 4-year CAGR
- +17.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.79M | -17.4% |
| FY2024 | 2024-12-31 | 82.02M | +103.6% |
| FY2023 | 2023-12-31 | 40.28M | -10.8% |
| FY2022 | 2022-12-31 | 45.14M | +26.5% |
| FY2021 | 2021-12-31 | 35.67M | — |
Operating Expenses vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 operating expenses of $59.97M is the 4th highest of the 5 companies compared; the peer median is $130.85M.
- Its year-over-year change of -41.2% is the lowest of 5, against a peer median of +35.3%.
- Over three fiscal years its annual growth of +14.5% compares with a peer median of +47.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $179.4M | +33.6% | +47.1% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $175.24M | +80.5% | +86.6% | 5275.0% |
| LTM Mar 2026 | $86.47M | +11.3% | -2.0% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $59.97M | -41.2% | +14.5% | — |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| Peer median (excluding CLYM) | $130.85M | +35.3% | +47.1% | 5275.0% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 97K |
| Gross Profit | 0 | 0 | 0 | 0 | (97K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.32M | 26.21M | 15.41M | 14.34M | 46.62M |
| Selling, General & Admin | 12.35M | 18.92M | 24.86M | 16.03M | 21.17M |
| Operating Expenses | 35.67M | 45.14M | 40.28M | 82.02M | 67.79M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| EBITDA | (47.48M) | (45.24M) | (35.12M) | (30.36M) | (59.75M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.67M) | (45.14M) | (40.28M) | (82.02M) | (67.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.38M | 4.62M | 8.13M | 8.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11.81M) | (109K) | 5.16M | 8.12M | 8.03M |
| Income Before Tax | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| EPS (Diluted) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| Weighted Avg Shares | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
| Weighted Avg Shares (Diluted) | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.